The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): A phase II study with biomarker analysis.
 
Hsiang-fong Kao
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Merck KGaA; MSD; Ono Pharmaceutical; Roche
Consulting or Advisory Role - Novartis
Speakers' Bureau - Boehringer Ingelheim; Bristol-Myers Squibb; Merck KGaA; MSD; Ono Pharmaceutical; Roche
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Bin-Chi Liao
No Relationships to Disclose
 
Yen-Lin Huang
No Relationships to Disclose
 
Huai-Cheng Huang
No Relationships to Disclose
 
Chun-Nan Chen
No Relationships to Disclose
 
Tseng-Cheng Chen
No Relationships to Disclose
 
Yuan-Jing Hong
No Relationships to Disclose
 
Ching-Yi Chan
No Relationships to Disclose
 
Ruey-Long Hong
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Ono Pharmaceutical (Inst)